(Q78508116)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12429287%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

editorial

0 references

title

Hormonal therapy for prostate cancer: primum non nocere (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12429287%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

author name string

Aaron J Milbank

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12429287%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Robert Dreicer

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12429287%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

Eric A Klein

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12429287%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

language of work or name

English

0 references

publication date

1 November 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12429287%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12429287%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

volume

60

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12429287%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12429287%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

page(s)

738-741

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12429287%20AND%20SRC:MED&resulttype=core&format=json

Hormone therapy for prostate cancer: a topical perspective

14 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Hormonal therapy in the management of prostate cancer: from Huggins to the present

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Neoadjuvant hormonal therapy: the Canadian experience

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Hormonal treatment before radical prostatectomy: a 3-year followup

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Early androgen deprivation for prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Early hormonal therapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901867-8

7 January 2021

10.1016/S0090-4295(02)01867-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12429287%20AND%20SRC:MED&resulttype=core&format=json

14 December 2019

1 reference